Plain-English translation of NCT06716281 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a treatment called IxCell hUC-MSC-O, which uses stem cells from umbilical cord tissue, injected directly into the knee joint. These stem cells can potentially reduce inflammation, slow cartilage damage, and relieve pain in people with knee osteoarthritis. Researchers will compare this treatment to a placebo injection to see if it really works.
Knee osteoarthritis is a chronic condition that causes ongoing pain even after standard treatments like anti-inflammatory drugs and injections. This trial is testing whether this medication might offer a new option for people whose pain hasn't improved with existing therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the stem cell injection or a placebo injection into your knee. Neither you nor the study staff will know which treatment you received (this is called a double-blind study). You will need to attend follow-up visits to have your pain and knee function checked over time. The study will track how much your pain improves and whether you experience any side effects from the injection.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Shanghai IxCell Biotechnology Co., LTD
Enrollment target
~398 participants
Started
January 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years – 80 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jie Zhao
The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.